Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 881

Sort by

Sort Order Select

Journal Articles

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Peter Duggan, MD FRCPC, Donna E. Reece, MD, Kevin Song, MD, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD BSc, Martha L Louzada, MDMSc, Hira S Mian, MD, Michael Sebag, MD PhD FRCPC, Darrell J White, MD, Julie Stakiw, MD, Richard Leblanc, MD FRCPC, Esther Masih-Khan, Eshetu G Atenafu, M.Sc., P.Stat, Rami Kotb, MD, Muhammad Aslam, MD, Anthony Reiman, MD, Engin Gul, BS, MBA, Christopher P. Venner, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139689

Published: 2020

Journal Articles

Genetic Heterogeneity of KLF1, a Master Regulator of Erythropoiesis, Revealed an Autosomal Recessive Ψβ-Thalassemia and a Very Strong Promoter In Vivo

Laura Grech, PhD MSc, B.Sc, Joseph Borg, PhDMSc,BSc, Ruth Galdies, M.Sc BPharm, Carmen Attard, Christian A. Scerri, MD PhD, Sjaak Philipsen, PhD, Alexander E. Felice

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-143018

Published: 2020

Journal Articles

Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computational Biology Modeling Approach: Mycare-021-01

Scott Howard, MD, Prashant Ramachandran Nair, B.Tech., Himanshu Grover, M.S., Anuj Tyagi, M.Sc., Pallavi Kumari, M.Sc., Samiksha Avinash Prasad, M.Sc., Upasana Mitra, M.Sc., Deepak Anil Lala, B.Tech., Humera Azam, M.Sc., Neha Gupta, M.Sc., Subrat Mohapatra, M.Sc., Poornachandra G, B.Tech., Nirjhar Mundkur, Michele Dundas Macpherson, B.A.Sc., Shweta Kapoor, M.Sc.

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140617

Published: 2020

Journal Articles

Monosomy 7 and Co-Occurrent Genomic Aberrations Determine Chemotherapy Response in Acute Myeloid Leukemia (AML) Patients Using the Cellworks Omics Biology Model (CBM): Mycare-021-04

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-140087

Published: 2020

Journal Articles

Healthcare Utilization and Costs Associated with Different Treatment Protocols for Newly Diagnosed Childhood Acute Lymphoblastic Leukemia: A Population-Based Study

Sumit Gupta, MD, Nicole Mittman, PhD MSc, Petros Pechlivanoglou, M.Sc., PhD, Qing Li, MSc, Uma Athale, MD MBBS, MSc, Mylene Bassal, MD, Vicky R. Breakey, BSc,MDFRCPC, Paul J. Gibson, MD, Mariana Silva, MD FRCPC, Veda Zabih, Jason Pole, PhD, Rinku Sutradhar, PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136365

Published: 2020

Journal Articles

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Nathan Radakovich, BA, David A. Sallman, MD, Rena J. Buckstein, MD FRCPC, Andrew M. Brunner, MD, Sudipto Mukherjee, MD PhD MPH, Rami Komrokji, MD, Najla Al Ali, M.Sc, Jacob Shreve, MD MS, Yazan Rouphail, Cassandra M Kerr, MS, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-139815

Published: 2020

Journal Articles

Pediatric-Onset Evans Syndrome Is Associated with Broad Immunopathological Manifestations, High Treatment Burden and Mortality in Long-Term Follow-up

Blood (2020) 136 (Supplement 1): 20–22.

https://doi.org/10.1182/blood-2020-133778

Published: 2020

Journal Articles

Administration of KER-047, a Novel ALK2 Inhibitor, Elicited Robust and Sustained Increases in Serum Iron in Healthy Participants

Claudia Ordonez, MD, Snyder Ben, MD, Rachel Barger, Timna Serino, Claire C Tseng, PhD, Christopher Rovaldi, M.Sc, Jenn Lachey, Jasbir Seehra

Blood (2020) 136 (Supplement 1): 13.

https://doi.org/10.1182/blood-2020-140323

Published: 2020

Journal Articles

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Claire Andrews, Taylor Young, Eshetu G Atenafu, M.Sc., P.Stat, Sarit E Assouline, MD MSc, Joseph M Brandwein, MD, Steven M Chan, MD PhD, Signy Chow, MD FRCP(C), Dina Khalaf, BSc, MSc, MD, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MD, Dawn Maze, MDFRCPC,MSc, Mark D. Minden, Caroline J McNamara, MBBS, Tracy Murphy, MDFRCP,FRCPath, David Sanford, MD, Aaron D Schimmer, MD PhD, Andre C. Schuh, Karen W.L. Yee, MD, Hassan Sibai, MBBS

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-142990

Published: 2020

Journal Articles

Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group

Mary B. Callanan, PhD, Elizabeth Macintyre, PhD MD, Marie-Helene Delfau-Larue, MD PhD, Catherine Thieblemont, MD PhD, Lucie Oberic, MD, Emmanuel Gyan, MD PhD, Krimo Bouabdallah, MD, Rémy Gressin, MD, Gandhi Damaj, MD PhD, Olivier Casasnovas, MD, Vincent Ribrag, MD, Samuel Griolet, Bénédicte Burlet, Benjamin Tournier, PhD, Sylviane Ragot, M.Sc, Caroline Bodet-Milin, Olivier Hermine, Steven Le Gouill, MD PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-140457

Published: 2020

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-134611

Published: 2020

Journal Articles

Prediction of Clinical Response for Frontline Treatment of Acute Myeloid Leukemia (AML) Patients Using the Cellworks Omics Biology Model (CBM): Mycare-021-02

Michael Castro, MD, Prashant Ramachandran Nair, B.Tech., Himanshu Grover, M.S., Ansu Kumar, M.Sc., Ashish Agarwal, B.V.Sc., Rakhi Purushothaman Suseela, B.Tech., Reshma P Gopi, M.Sc., Naga Ganesh, B.Tech., Vijayashree P Shyamasundar, M.Sc., Shruthi Kulkarni, B.E., Mohammed Sauban, B.E., Ashokraja Balla, M.Tech., Srushti P Chafekar, M.Sc., Sayantani Roy Choudhury, M.Sc., Nirjhar Mundkur, Michele Dundas Macpherson, B.A.Sc., Shweta Kapoor, M.Sc., Scott Howard, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-141479

Published: 2020

Journal Articles

Evaluating the PET Parameters SUVmax and TMTV in the Setting of Autologous Stem Cell Transplantation for DLBCL

Rachel Brown, MD, Alessandro Lambertini, MD, Michael S Hofman, MBBS (Hons), FRACP, FAANMS, Mathias Bressel, M.Sc, Michael P Macmanus, MD MRCP, MBBS, Andrew Wirth, MBBS, MD FRACP, FRANZCR, John F. Seymour, Michael Dickinson, DMed Sci, Belinda Campbell, MBBS, MMed, FRANZCR

Blood (2020) 136 (Supplement 1): 38.

https://doi.org/10.1182/blood-2020-135920

Published: 2020

Journal Articles

Molecular Imaging of Chimeric Antigen Receptor T Cells By ICOS-Immunopet

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-136331

Published: 2020

Journal Articles

Detection of M-Protein in Acetonitrile Precipitates of Serum Using MALDI-TOF Mass Spectrometry: A Novel Methodology

Nikita Mehra, MDDM, Gopal Gopisetty, PhD, Jayavelu S, M.Sc, Arivazhagan Rajamanickam, PhD, Shirley Sundersingh, MD PhD, Jayachandran PK, MD MRCP, DM, Parathan Karunakaran, MD, Krishnarathinam Kannan, MD DM, Venkatraman Radhakrishnan, MD DM, Tenali Gnana Sagar, MD DM, Thangarajan Rajkumar, MD, D.M., PhD, D.Sc., FAMS

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-141301

Published: 2020

Journal Articles

Impact of Age, Comorbidity, and Polypharmacy on Treatment and Survival for Aggressive Non-Hodgkin Lymphoma

Laura Tapley, MD, Pamela Skrabek, MD, Pascal Lambert, M.Sc., Jenniebie Bravo, M.Sc., Kathleen Decker, PhD, Piotr Czaykowski, MD, Donna Turner, MD, Phil St. John, MD, David Dawe, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-142591

Published: 2020

Journal Articles

SF3B1 Splicing Mutation in the Context of Therapy Related MDS

Virginia Olivia Volpe, MD, Najla Al Ali, M.Sc, Onyee Chan, MD, Eric Padron, MD, David A. Sallman, MD, Rami S. Komrokji, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-138833

Published: 2020

Journal Articles

Assessment of Cellworks Omics Biosimulation Therapy Response Predictions for Patients with Acute Myeloid Leukemia (AML) Using Cellworks Singula™: Mycare-020-01

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-142184

Published: 2020

Journal Articles

Identification of Pharmacogenomic Single Nucleotide Polymorphism Variants As Contributors to Toxicity Phenotype in the Treatment of Acute Childhood Leukemia

Trisha Larkin, MDMBA, Abdelrahman H Elsayed, MSc, Roya Rafiee, M.Sc., PhD, Natasha Emanuel, Beate Greer, Biljana N. Horn, MD, Jatinder K Lamba, MSc, PhD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-143195

Published: 2020

Journal Articles

AML Associated Mesenchymal Stroma Cells Support Growth of AML Cells As a Result of Activated Notch Signaling and This Can be Targeted By Dexamethasone

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-134177

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Genetic Heterogeneity of KLF1, a Master Regulator of Erythropoiesis, Revealed an Autosomal Recessive Ψβ-Thalassemia and a Very Strong Promoter In Vivo

Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computational Biology Modeling Approach: Mycare-021-01

Monosomy 7 and Co-Occurrent Genomic Aberrations Determine Chemotherapy Response in Acute Myeloid Leukemia (AML) Patients Using the Cellworks Omics Biology Model (CBM): Mycare-021-04

Healthcare Utilization and Costs Associated with Different Treatment Protocols for Newly Diagnosed Childhood Acute Lymphoblastic Leukemia: A Population-Based Study

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Pediatric-Onset Evans Syndrome Is Associated with Broad Immunopathological Manifestations, High Treatment Burden and Mortality in Long-Term Follow-up

Administration of KER-047, a Novel ALK2 Inhibitor, Elicited Robust and Sustained Increases in Serum Iron in Healthy Participants

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Prediction of Clinical Response for Frontline Treatment of Acute Myeloid Leukemia (AML) Patients Using the Cellworks Omics Biology Model (CBM): Mycare-021-02

Evaluating the PET Parameters SUVmax and TMTV in the Setting of Autologous Stem Cell Transplantation for DLBCL

Molecular Imaging of Chimeric Antigen Receptor T Cells By ICOS-Immunopet

Detection of M-Protein in Acetonitrile Precipitates of Serum Using MALDI-TOF Mass Spectrometry: A Novel Methodology

Impact of Age, Comorbidity, and Polypharmacy on Treatment and Survival for Aggressive Non-Hodgkin Lymphoma

SF3B1 Splicing Mutation in the Context of Therapy Related MDS

Assessment of Cellworks Omics Biosimulation Therapy Response Predictions for Patients with Acute Myeloid Leukemia (AML) Using Cellworks Singula™: Mycare-020-01

Identification of Pharmacogenomic Single Nucleotide Polymorphism Variants As Contributors to Toxicity Phenotype in the Treatment of Acute Childhood Leukemia

AML Associated Mesenchymal Stroma Cells Support Growth of AML Cells As a Result of Activated Notch Signaling and This Can be Targeted By Dexamethasone

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only